Earnings summaries and quarterly performance for Esperion Therapeutics.
Executive leadership at Esperion Therapeutics.
Board of directors at Esperion Therapeutics.
Research analysts who have asked questions during Esperion Therapeutics earnings calls.
Joseph Pantginis
H.C. Wainwright & Co.
3 questions for ESPR
Also covers: ARMP, BCDA, BLRX +15 more
SB
Serge Belanger
Needham & Company
3 questions for ESPR
Also covers: AMPH, ARQT, BCRX +13 more
Jason Zemansky
Bank of America
2 questions for ESPR
Also covers: ABOS, BBIO, CYTK +5 more
JF
Jessica Fye
JPMorgan Chase & Co.
2 questions for ESPR
Also covers: ALKS, ALNY, AMRN +23 more
Kristen Kluska
Cantor Fitzgerald
2 questions for ESPR
Also covers: ABEO, ADMA, AQST +24 more
Tom Shrader
BTIG
2 questions for ESPR
Also covers: ABOS, ALDX, ALEC +4 more
Georgia Bank
Jefferies
1 question for ESPR
PC
Paul Choi
Goldman Sachs
1 question for ESPR
Also covers: AMRN, ARVN, ASND +13 more
Recent press releases and 8-K filings for ESPR.
Esperion Therapeutics Announces Acquisition of Corstasis Therapeutics
ESPR
M&A
Product Launch
New Projects/Investments
- Esperion Therapeutics has entered into a definitive agreement to acquire Corstasis Therapeutics, expanding its cardiovascular franchise.
- The acquisition includes Enbumyst, the first and only FDA-approved nasal spray loop diuretic for edema associated with congestive heart failure, which was approved in September 2025.
- The financial terms of the deal include an upfront cash payment of $75 million, royalties on worldwide Enbumyst sales, and up to $180 million in potential milestone payments.
- This acquisition is expected to accelerate double-digit revenue growth and provides entry into a potential $4+ billion addressable outpatient congestive heart failure market.
- Esperion plans to leverage its established cardiovascular commercial infrastructure to launch Enbumyst and aims to achieve sustainable profitability in 2026.
2 days ago
Esperion Therapeutics Announces Acquisition of Corstasis Therapeutics
ESPR
M&A
New Projects/Investments
Product Launch
- Esperion Therapeutics is acquiring Corstasis Therapeutics.
- The acquisition includes an upfront cash payment of $75 million, up to $180 million in regulatory- and commercial-based milestones, and low-double digit royalties on sales of Enbumyst and follow-on products.
- Corstasis's lead asset, Enbumyst (bumetanide nasal spray), was FDA-approved in September 2025 for adults with edema associated with congestive heart failure, and hepatic and renal disease.
- This strategic acquisition expands Esperion's focus into complementary treatment for edema in congestive heart failure patients and provides entry into a potential $4 billion+ US addressable outpatient CHF market.
- Esperion plans to finance the upfront cash payment with a combination of debt and royalty monetization.
2 days ago
Esperion Therapeutics Announces Acquisition of Corstasis Therapeutics and Enbumyst
ESPR
M&A
Product Launch
New Projects/Investments
- Esperion Therapeutics announced a definitive agreement to acquire Corstasis Therapeutics, expanding its cardiovascular franchise.
- The acquisition includes Enbumyst, the first and only FDA-approved nasal spray loop diuretic for edema associated with congestive heart failure, which was approved in September 2025.
- The deal terms involve an upfront cash payment of $75 million, royalties on worldwide Enbumyst sales, and up to $180 million in potential milestone payments.
- This acquisition is expected to leverage Esperion's established cardiovascular commercial infrastructure, expand its product portfolio, and accelerate double-digit revenue growth.
- Enbumyst holds strong intellectual property (IP) protection until 2040.
2 days ago
Esperion Therapeutics acquires Corstasis Therapeutics
ESPR
M&A
New Projects/Investments
Revenue Acceleration/Inflection
- Esperion Therapeutics has entered into a definitive agreement to acquire Corstasis Therapeutics, adding ENBUMYST, the first and only FDA-approved nasal spray loop diuretic for edema associated with congestive heart failure, to its portfolio.
- The acquisition includes an upfront cash payment of $75 million, royalties on worldwide ENBUMYST sales, and up to $180 million in potential milestone payments tied to commercial and regulatory achievements.
- This strategic move is expected to leverage Esperion's existing cardiovascular commercial infrastructure, accelerate double-digit revenue growth, and provide entry into a potential $4+ billion addressable outpatient congestive heart failure market.
- ENBUMYST, approved in September 2025, targets an addressable U.S. market of 2.1 million annual heart failure episodes, representing a $5 billion market opportunity, with strong intellectual property extending to 2040.
- Esperion anticipates achieving sustainable profitability in 2026 as a result of this and other strategic initiatives.
2 days ago
Esperion Therapeutics Announces Acquisition of Corstasis Therapeutics
ESPR
M&A
New Projects/Investments
Product Launch
- Esperion Therapeutics, Inc. (ESPR) has entered into an Agreement and Plan of Merger to acquire Corstasis Therapeutics Inc..
- The financial terms of the acquisition, detailed in the March 2, 2026 agreement, include an upfront cash payment and potential additional payments for milestones and royalties :
| Metric | Q4 2025 |
|---|---|
| Upfront Payment ($USD Millions) | $75 |
| Maximum Milestone Payments ($USD Millions) | $180 |
| Royalties | Low double-digit |
- The primary asset acquired is ENBUMYST™ (bumetanide nasal spray), an FDA-approved treatment for edema associated with congestive heart failure, hepatic, and renal disease, which was approved on September 12, 2025.
- This transaction is expected to close in the second quarter of 2026 and aims to strengthen Esperion's commercial portfolio by targeting a U.S. market with a potential opportunity exceeding $4 billion.
2 days ago
Esperion Therapeutics to Acquire Corstasis Therapeutics
ESPR
M&A
New Projects/Investments
- Esperion Therapeutics entered a merger agreement on March 2, 2026, to acquire Corstasis Therapeutics for $75 million in cash up front, with potential additional payments of up to $180 million plus royalties. The deal is expected to close in the second quarter of 2026.
- The acquisition brings Enbumyst, an FDA-approved bumetanide nasal spray for edema associated with congestive heart failure and hepatic and renal disease, into Esperion's portfolio, expanding its reach into metabolic, hepatic, and renal care. Enbumyst was approved in September 2025.
- Esperion plans to fund the acquisition using existing credit facilities and by monetizing Japanese royalties.
- Analysts note Esperion's challenging financial profile, including negative margins, insider selling activity (63,787 shares sold by four insiders in the past three months), and an Altman Z-Score of -5.3, placing the firm in a 'distress' zone and increasing bankruptcy possibility within two years.
2 days ago
Esperion Therapeutics to Acquire Corstasis Therapeutics
ESPR
M&A
New Projects/Investments
- Esperion Therapeutics has entered into a definitive agreement to acquire Corstasis Therapeutics.
- The acquisition includes Enbumyst™ (bumetanide nasal spray), the first and only FDA-approved nasal spray loop diuretic for edema associated with congestive heart failure, approved in September 2025.
- The financial terms involve an upfront cash payment of $75 million, royalties on worldwide Enbumyst sales, and up to $180 million in potential milestone payments.
- The transaction is expected to close in the second quarter of 2026 and aims to accelerate Esperion's Vision 2040, targeting a U.S. market opportunity exceeding $4 billion.
2 days ago
Esperion Therapeutics to Acquire Corstasis Therapeutics
ESPR
M&A
New Projects/Investments
- Esperion Therapeutics has entered into a definitive agreement to acquire Corstasis Therapeutics Inc., a privately-held, commercial-stage biopharmaceutical company.
- The acquisition includes Enbumyst™ (bumetanide nasal spray), the first and only FDA-approved nasal spray diuretic for edema associated with congestive heart failure, hepatic, and renal disease.
- Under the terms, Esperion will make an upfront cash payment of $75 million, with Corstasis shareholders eligible for up to $180 million in potential milestone payments and low double-digit royalties on Enbumyst sales.
- The transaction, expected to close in the second quarter of 2026, is anticipated to accelerate Esperion's double-digit revenue growth, targeting a U.S. market opportunity exceeding $4 billion.
2 days ago
Esperion Settles Patent Litigation with Alkem Laboratories
ESPR
Legal Proceedings
- Esperion (NASDAQ: ESPR) has entered into a settlement agreement with Alkem Laboratories Ltd. to resolve patent litigation.
- The agreement prevents Alkem from marketing generic versions of NEXLETOL and NEXLIZET in the United States prior to April 19, 2040.
- Ongoing patent litigation against other defendants, including Aurobindo Pharma Limited, MSN Pharmaceuticals Inc., Renata Limited, and Sandoz Inc., is still pending.
Feb 17, 2026, 1:00 PM
Esperion Outlines Vision 2040, Reports Preliminary 2025 Financials, and Provides 2026 Guidance
ESPR
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- Esperion reported preliminary U.S. net sales of $156 million-$160 million and total revenue of $400 million-$408 million for the past year, with retail prescriptions growing 34% year over year. The company holds $168 million in preliminary cash and aims for sustainable profitability in 2026.
- The company's "Vision 2040" aims for at least five marketed products by that year, driven by pipeline advancements including a triple combination product expected to launch in H2 2027 and ESP-2001 for primary sclerosing cholangitis, with clinical trials anticipated before the end of 2026.
- Esperion is expanding globally, with a recent launch in Japan and planned launches in Canada, Israel, Australia, and New Zealand by the end of 2026. Market exclusivity for bempedoic acid products is secured with some generic filers until 2040.
- Operating expense guidance for 2026 includes R&D of $40-$50 million and SG&A of $170-$195 million, for a total OPEX of $210-$245 million.
Jan 14, 2026, 10:15 PM
Quarterly earnings call transcripts for Esperion Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more